These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34522598)

  • 41. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence.
    Aggarwal B; Gogtay J
    Expert Rev Respir Med; 2014 Jun; 8(3):349-56. PubMed ID: 24802511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.
    Scichilone N; Benfante A; Morandi L; Bellini F; Papi A
    Patient Relat Outcome Meas; 2014; 5():153-62. PubMed ID: 25473323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.
    Ferguson GT; Hickey AJ; Dwivedi S
    Respir Med; 2018 Jan; 134():16-23. PubMed ID: 29413503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization.
    Ni R; Muenster U; Zhao J; Zhang L; Becker-Pelster EM; Rosenbruch M; Mao S
    J Control Release; 2017 Mar; 249():11-22. PubMed ID: 28109773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic optimisation of asthma treatment.
    Taburet AM; Schmit B
    Clin Pharmacokinet; 1994 May; 26(5):396-418. PubMed ID: 7914480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polymer-Based Novel Lung Targeted Delivery Systems.
    Elmowafy E; Osman R; Ishak RA
    Curr Pharm Des; 2017; 23(3):373-392. PubMed ID: 27799039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model Calculations of Regional Deposition and Disposition for Single Doses of Inhaled Liposomal and Dry Powder Ciprofloxacin.
    Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):49-60. PubMed ID: 28708440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
    Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
    Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma.
    Pavia D
    Respirology; 1997; 2 Suppl 1():S5-10. PubMed ID: 9400688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of nicotine release from nicotine-loaded chitosan nanoparticles dry powder inhaler formulations via locomotor activity of C57BL/6 mice.
    Wang H; Holgate J; Bartlett S; Islam N
    Eur J Pharm Biopharm; 2020 Sep; 154():175-185. PubMed ID: 32682941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of concentrated ambient particles on normal and hypersecretory airways in rats.
    Harkema JR; Keeler G; Wagner J; Morishita M; Timm E; Hotchkiss J; Marsik F; Dvonch T; Kaminski N; Barr E
    Res Rep Health Eff Inst; 2004 Aug; (120):1-68; discussion 69-79. PubMed ID: 15543855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug metabolism in the lungs: opportunities for optimising inhaled medicines.
    Enlo-Scott Z; Bäckström E; Mudway I; Forbes B
    Expert Opin Drug Metab Toxicol; 2021 May; 17(5):611-625. PubMed ID: 33759677
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
    Patel B; Gupta V; Ahsan F
    J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
    Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
    Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.
    Tahara K; Tomida H; Ito Y; Tachikawa S; Onodera R; Tanaka H; Tozuka Y; Takeuchi H
    Int J Pharm; 2016 May; 505(1-2):139-46. PubMed ID: 27012982
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
    Sovani MP; Whale CI; Tattersfield AE
    Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Substance deposition assessment in obstructed pulmonary system through numerical characterization of airflow and inhaled particles attributes.
    Lalas A; Nousias S; Kikidis D; Lalos A; Arvanitis G; Sougles C; Moustakas K; Votis K; Verbanck S; Usmani O; Tzovaras D
    BMC Med Inform Decis Mak; 2017 Dec; 17(Suppl 3):173. PubMed ID: 29297393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease.
    Collier DJ; Wielders P; van der Palen J; Heyes L; Midwinter D; Collison K; Preece A; Barnes N; Sharma R
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1301-1313. PubMed ID: 32606640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.